HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Lurasidone: a new treatment option for bipolar depression-a review.

Abstract
Depressive episodes in bipolar disorder contribute to significant morbidity and mortality. Until recently, only quetiapine and an olanzapine-fluoxetine combination were approved to treat bipolar depression. Recently, lurasidone was approved to treat bipolar depression either as monotherapy or adjunctively with lithium or valproate. Lurasidone was well- tolerated, and commonly observed adverse reactions (incidence ≥5% and at least twice the rate for placebo) were akathisia, extrapyramidal symptoms, and somnolence. There were no significant metabolic or electrocardiogram abnormalities. It is taken with food to ensure maximal absorption, and dose should be adjusted in patients who receive moderate CYP450 inhibitors or inducers and in patients with renal disease.
AuthorsRadhika Bawa, Jonathan R Scarff
JournalInnovations in clinical neuroscience (Innov Clin Neurosci) 2015 Jan-Feb Vol. 12 Issue 1-2 Pg. 21-3 ISSN: 2158-8333 [Print] United States
PMID25852975 (Publication Type: Journal Article, Review)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: